The estimated Net Worth of Daniel Raynor is at least $31.6 Million dollars as of 15 March 2018. Daniel Raynor owns over 7,215 units of ANI Pharmaceuticals Inc stock worth over $15,698,643 and over the last 11 years Daniel sold ANIP stock worth over $15,912,910.
Daniel has made over 5 trades of the ANI Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Daniel sold 7,215 units of ANIP stock worth $439,033 on 15 March 2018.
The largest trade Daniel's ever made was selling 200,000 units of ANI Pharmaceuticals Inc stock on 12 March 2015 worth over $12,600,000. On average, Daniel trades about 26,864 units every 146 days since 2013. As of 15 March 2018 Daniel still owns at least 289,003 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Daniel Raynor stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is C/O BIOSANTE PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: